Biotech News

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

Immix Biopharma (IMMX)Immix BiopharmaConference / presentation

LOS ANGELES, CA, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced that it will present at the 45th Annual J.P. Morgan Healthcare Conference being held January 11-14, 2027 in San Francisco, CA.

A link to access the replay, when available, will be...

Related news

Immix Biopharma

Cell-Therapy Developer Immix Biopharma is a clinical-stage biotechnology company developing autologous CAR T-cell therapies for hematologic diseases. Its lead program is designed around a differentiated BCMA-targeted construct. NXC-201 Lead Program NXC-201 is a BCMA-directed CAR T-cell therapy with a proprietary binder, CD8 hinge, and...

Recent company news

Stock data

Close
7.04 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States